• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Peperidine derivs. of formula (I) are new: (R1 = H, branched, linear or cyclic, opt. unsatd., aliphatic hydrocarbyl, aryl or heterocyclyl, all opt. substd.; R2 = H, OH, OR', SH, SR', NH2, NHR', NR'R", NH2CH2, R'NHCH2, R'R"NCH2, COOH, COOR', HOCH2, R'CONHCH2, R'CONR"CH2, R'SO2NHCH2, R'SO2NR"CH2, R'NHCONHCH2, R'NHCSNHCH2, R'OCONHCH2, SO3H, CN, CONH2, CONHR' or CONR'R"; R3 can be as R1 but is pref H, CH3, CH2OH, CH2NH2, CH2NHR', CH2NR'R", R'CONH.CH2, R'CONR"CH2, HalCH2, R'OCH2, R'COOCH2, R'SO2OCH2, R'SO2NHCH2, R'NH.CONHCH2, R'NHCSNH.CH2, R'OCONHCH2, CN, COOH, COOR', CONH2, CONHR', R'SO2NR"CH2, CONR'R"; R' and R" are as for R1; when (i) R3 = CH2OH; R2 = H or OH; (ii) R3 = CH2NH2 and R2 = OH; and also (iii) when R3=H, R2=H, OH, SO3H, CN or CH2NH2, R1 cannot be H). (I) inhibit alpha-glucosidases, esp. disaccharidases, so are useful in treating pre-diabetes, gastritis, obstipation, caries, gastro-intestinal infections, meterorism, flatulence, hypertension, atherosclerosis and esp. adiposity, diabetes and hyperlipoproteinaemia. They are also useful as animal feed additives to improve the meat-fat distribution.
    公开号:SU1014470A3
    申请号:SU813276192
    申请日:1981-04-27
    公开日:1983-04-23
    发明作者:Юнге Бодо；Петер Краузе Ханс；Мюллер Лутц；Пульс Вальтер
    申请人:Байер Аг (Фирма)；
    IPC主号:
    专利说明:

     l "i The invention relates to the preparation of derivatives of 3, t, 5 trioxypiperidine of the general formula: ylNH but- (Usn-sh-so-in. 1) - (but where R is alkyl C -C, propylaminogroup, alkoxy phenyl is unsubstituted or substituted by chlorine, is not 1.mol. by methoxy or methylsulfonyl, benzyl, carboxyethyl or the group -NH- (CH2) -R, where R is hydrogen, methyl, ethoxycarbonyl, phenyl, benzoylaminomethyl cyano or amino group, and means 0-6 which can be used in the chemical and pharmaceutical industry as a remedy for diabetes, giparlidemii and obesity, as well as substances affecting the ratio of meat / fat in animals, the acylation of amines chlorine with acid anhydrides and acid anhydrides is known, by acids in the presence of carbodiimido with isocyanates Cl. The invention is based on the well-known method of obtaining new compounds, possessing valuable pharmaceutical properties. The goal is achieved by the fact that according to the method of producing 3, + 5 trioxypiperidine derivatives of the general formula 1j where R has the indicated values, a compound of the formula CHgOH is VL-NH but it is acylated. measures K 1-Methoxycarbonyl-Laminomethyl-1-desoxinoimyrimycin (R OCH3). 1.92 g of the compound of the formula is dissolved in 200 ml of water and 60 ml of methanol and the solution is mixed with I, ml of triethylamine. 1.2 ml of methyl chloroformate in 30 ml of ethyl acetate are added dropwise at 0-, stirred for k hours at room temperature. and the reaction mixture is evaporated. The resulting residue is dissolved in fetonol-water (8: 1), fed to a column containing anion exchanger in hydroxyl form and elgated with methanol-water (8: 1), the filtrate is evaporated and the residue is purified on a column containing cellulose using acetone in as a quotation. After recrystallization from ethanol, 1.9 g (76%) of pure product is obtained with m, pl. 157C. The following compounds are prepared analogously: 1-ethoxycarbonylaminomethyl -1-deoxinoimyrimycin (R) with t, mp, 169 172 ° C, yield - 77%; 1-butoxycarbonylamino-Tyl-1-deoxyenoimyrimycin (R) with m.p. 1b2loS Cf OUTPUT - 72%; 1-nonyloxycarbonylaminomethyl 1-deoxyenoimyrimycin (R) with m, pl, 172 G., yield 1-dodecyloxycarbonylaminomethyl-1-deoxyoimyrimycin (R OS H, / c m.p., yield - 70%. Example 2. 1 - (N -Phenylureidomethyl) -1-deoxinoimirimycin (R). Mix 9.0 mg of the compound of formula P in methanol-water (1: 1) mixture at 20 ° C for 15 min with 0.8 ml of phenyl isocyanate. Then, the temperature is gradually raised to room temperature. the solvent is separated on a cellulose-filled column and washed out with butanol containing 10% water. synoyriymycin, combines and seals the residue recrystallized from ethanol. Yield: 400 mg (25.8%) 1 (M-phenyl-ureidomethyl) -1-deoxinoimyrimycin with melting point 1 b1-1 b2 C, Analogously to Example 2, we obtain: 1 - (M - benzylureidomethyl) -1 Deozinoyriymycin (R NHgiCH j C N5-), t, pl „176 C, yield 26%; 1- (N-methiggureidomethyl) 1-deoxinoinomyrimycin with mp, (R NHCH), yield 35% J 1 (Mp butylureidomethyl) -1-disoxinoimyrimycin (R MH (CH) 5CH. from m.p. 152С, yield - 27.5%; 1- - (N 5-Cyanopentylureidomethyl) -1-desoxinoimyrimycin (R NH (CH4) CN with m.p., 1bO-1b5 C (from methanol), yield - 28.5%; 1- (NB-aminohexylureidomethyl) -1-deoxinomyrimycin (R NH (CHa) 6NH, i) with mp 178C, yield 32%. Example 3. (R). 1 - (N-Ethoxycarbonylmethylureidomethyl) -1-deoxinoimirimycin, 3.8j g of compound Formula IJ is dissolved in a mixture of 0 ml of water and 80 ml of 31 ethanol and a solution of 2.84 ml of isocyanatoacetic acid ethyl ester in 60 ml of acetic ester is added dropwise and stirred at 20-25 ° C for 18% and concentrated by chromatography on a cellulose containing column , using 85% acetone as eluent. Obtain 2.1 g (33.71) of product as a colorless foam. Example 4. 1-Acetamidomethyl-deoxinoimyrimycin (R CH3). To 3.8 g of compound of formula IJ 3 ml of acetic anhydride is added in 0 ml of methanol-water (1: 1) mixture at 0 ° C. Stir for 15 minutes at room temperature for 30 minutes and then evaporated to dryness in a rotary evaporator. The residue is dissolved in 60 ml of water and neutralized with a basic ion exchanger (OH-form). After removal of the ion exchanger, it is again evaporated to dryness and the residue is recrystallized twice from ethanol. Yield 3 g (, 1%) of 1-acetamidomethyl-1-deoxynomyrimycin with a melting point of 169-1 ° C. Analogously to example k, 1-benzoylaminomethyl-1-desoxinoimyrimycin (R) is obtained with m.p. 21 SB (from methanol), yield - 6.5%. Example S 1-Propionylamino methyl-1-deoxinomyrimycin (R 2.8 ml of propionic acid chloride was added dropwise to 2.88 g of compound of formula II and 0.975 g of potassium hydroxide in 3 ml of methanol and 30 ml of water. After mixing at 2 hours, 0.9 g of potassium hydroxide and 0.97 ml of prioric acid chloride are added once more. After two hours of stirring and the reaction mixture is evaporated, the residue is added with water, fed into the column containing Amberlite cation exchanger IP 120 hydrogen form, and eluted first with water and then dilute ammonia The ammonium eluate is evaporated to dryness and the residue is purified by chromatography on a column containing cellulose using an acetone / water mixture as an eluent. After recrystallization from methanol, 1.4 g (37.6) of product are obtained, mp 183-185 ° C. Similarly, the following compounds are obtained: 1- (isovaleryl-aminomethyl) -1-disoxyneoimyricycin (R CH2CH (CH3) 2 0 s, pl, ISSISS C, yield 36, 1-valerylaminomethyl-1-deoxinoimirimycin (R СЛН) с mp.191 C, yield - 37.5 ° e; 1-heptanoylaminomethyl-1-deoxynomyrimycin (R) with m.p. 20.c, yield - 38%; T-okUnoylaminomethyl-1-desoxinomyrimycin (R CN) with m.p. 205C, yield 37,%; 1 - ((-aminobutyrylaminomethyl) -1-deoxyenoimyrimycin (R () s.t.pl., yield - 38, 1- (N-6-benzoylaminohexylureidomethyl) -1-deoxyinoyrimycin with mp.195 ° C (R NH ( CH) CH j NHCOC Hg.), Yield 36 °, 2 °. Example 6. 1-C-Methoxybenzamidomethyl) -1-deoxinoimirimycin (R 4 -CH 3 O 3) 5, (g of compound of formula II is dissolved in a mixture of 14.1 ml water and +2.3 ml of methanol and mixed with 3.9 ml of triethylamine. 5.26 g of I-methoxybenzoic acid chloride is added, 21.21 ml of ethyl acetate. The mixture is stirred at room temperature for 2 hours, 5 are added. ml of ethanol, stirred for 1 hour; The solid product is filtered off with suction and washed with ethanol. LOT 5.35 g (58.3%) of colorless crystals with a melting point of 224-22 ° C (decomposition) is obtained. Likewise, 1-phenacetylamidomethyl-1-deoxyinomyrimycin (R CH) is obtained mp 1b -1b7s, yield 55.8%; 1- (3-methylbenzamidomethyl) -1-deoxinoimirimycin (R with mp 205 ° C, yield 56.5%; 1 - (- nitrobenzamidomethyl) - 1-deoxinomyrimycin (R t-N02 C Hy) with so pl. 246-248C (from water, yield 58, 2%; 1- - chlorobenzamidomethyl) - -deoxinoiomyrimycin (R -ClCfcHif) with m.p. 249 ° C, yield - 58.8%; - (k-methylbenzamidomethyl) - -deoxinoimirimycin (R t-CHijC H) with m.p. 242 C, yield - 60%; 1- (2-methylsulfonylbenzamidomethyl) -1-desoxinoimyrimycin (R Z-CHgO jiSrg N5-) with so pl. , yield - 59.1%. Example 7- 1- (3 Cyanopropionylaminomethyl) -1-deoxynomyriomycin (R CH,). 3 g of a compound of formula IJ in 30 ml of dimethylformamide and 3 ml of water are mixed with 3.1 g of dicyclohexylcarbodiimide and 1.5 g of 3-Cyanopropionic acid. The reaction mixture is stirred at room temperature in
    over night Then another 1.55 g of dicyclohexylcarbodiimide and Oj, 75 g of 3 cyanopropionic acid are added. The mixture is stirred at room temperature for 2 hours. It is then diluted with a hydrogen dioxide and the precipitate is filtered, the filtrate is evaporated, and the residue is purified by chromatography on a column containing cellulose using mixture acetone with water as eluent. After crystallization from ethanol, 2.0 g (.8) 7% of the product with the like are obtained. .
    Example 8. R C, j H4COOH, 1 (3 Carboxylpropionylaminomethyl) -1-deoxynomyrimycin,
    3.8 g of a compound of formula IJ in 80 ml of pyridine and 16 ml of water are mixed with 2, (ml of succinic acid chloride and the reaction mixture is stirred at room temperature for 3 hours. The mixture is evaporated and the residue is fed to a column containing Laues 1x28 hydroxyl ionite, followed by elution first with water, then with a mixture of water and ethanol (3: 1) and finally with acetic acid. The acetic eluate is evaporated and the residue is mixed with acetone. Sucked off, dissolved in water and again evaporated. Obtain 1.7 g (29, ( a) product with mp 19b197S.
    Properties of the derivative of 3 5 trioxypiperidine {R. PSN) illus. Riuts with the following.
    Determination of the degree of inhibition.
    This test in vitro makes it possible to determine the enzyme inhibitory activity of a substance by comparing the activity of a dissolved intestinal disaccharidase complex in the presence and absence of (100 value of inhibitor, 8 as a quality with: bstrata) use practically glucose-free sucrose (glucose 100 ppm). Definition The enzyme activity is based on the spectroscopic determination of glucose released by the reaction by glucose dehydrogenase and nicot amide adenine dinucleotide as a cofactor.
    One unit of sucrosease inhibitor (SIE) is defined as such inhibitory activity, which in a given initial test mixture restores a given saccharolytic
    activity per unit (unit of sucrase SE); a unit of sucrase determines the activity of enzymes, which, under these conditions, splits 1 µmol of sucrose per minute and this releases each time 1 µmol of glucose, which is determined by the test, and fructose, which is not detected by the test.
    The intestinal disaccharidase complex is obtained from the mucous membrane of the small intestine of the pig by tryptic digestion, precipitation from 66 ethanol at -20 ° C, absorption of the precipitate in 100 mM phosphate buffer pH 7.0 and dialysis against the buffer.
    10 μl of the test solution, which is prepared so that the extinction of the initial mixture is less than 101 undiluted disaccharidase complex in 0.1 M maleic buffer pH 6.25, is preincubated at 37 ° C for 10 minutes. The dilution of the disaccharidase complex should be set to an activity of 0.1 SE / ml.
    Then, the saccharolytic reaction is started by adding 100 µl of a solution of O, m of sucrose (Serve 35579) in 0.1 m maleic buffer pH 6.25 after 20 min of incubation and the reaction is stopped by adding 1 ml of glucose-hydrogenase reagent (1 bottle of glucose mixture and lyophilized dehydrogenase (Megsk H053 and a solution of 331.7 mg | 1-nicotinamide-adenine dinucleotide (free acid, Beringer purity 1 in 250 ml of 0.5 M Tris buffer, pH 7.6, To determine glucose, the mixture is incubated in for 30 min at 37 ° C and then photometric with respect to the reagent at H / J (with the enzyme without sugar).
    The calculation of the inhibitory activity is complicated by the fact that a slight change in the test system, for example, a value of 100, which varies slightly from definition to definition, has an effect on the test result that cannot be ignored. These difficulties are avoided by the fact that with each definition a standard is also taken. The sucrose inhibitor of formula O, which has a specific inhibition activity of 77,700 SIE / r, serves as the standard. With knowledge of extinction differences at and and the value of 10 and the mixture hindered by the standard,
    7loU + yO8
    from the difference of extinction and inhibited 465000 SIE / r; 1-methoxycarbonylproduct solution of the mixture, taking vz-aminomethyl-1-deoxinoinomyrimycin
    the amount of inhibitor known-1500000 5 1E / g. to calculate his braking effect
    activity, expressed in units of im.The proposed method allows a sucrose killer per gram. to produce new compounds possessing
    Specific inhibitory secretion of chemical-pharmaceutical
    Activity: 1-deoxynomyurimicin properties.
    权利要求:
    Claims (1)
    [1]
    1 METHOD FOR PRODUCING 3,4,5-TRIOXYPIPERIDE DERIVATIVES & IN GENERAL FORMULA where R is C ^ -C 7 alkyl, propylamino, C ^ -C 72 alkoxyl, phenyl unsubstituted or substituted with chlorine, methyl, methoxy or methylsulfonylmethyl, benzyl, Group
    -nh- (ch 2 ) “-r ', where R 1 is hydrogen, methyl, ethoxycarbonyl, phenyl, benzoylaminomethyl, cyano or amino group, n means 0-6, characterized in that the compound of the formula
    CH 2 OH
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1014470A3|1983-04-23|Process for preparing derivatives of 3,4,5-thioxypipidine
    USRE34580E|1994-04-05|Process for the preparation of a stable modification of torasemide
    US5274098A|1993-12-28|Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them
    US4119620A|1978-10-10|Novel dipeptide derivatives, salts thereof, and method of measuring enzyme activity
    US4086415A|1978-04-25|Nitrosourea derivatives of glycosides
    SU1604158A3|1990-10-30|Method of producing derivatives of griseolic acid
    Shenbagamurthi et al.1983|Design of anticandidal agents: synthesis and biological properties of analogs of polyoxin L
    CA1174973A|1984-09-25|Process for preparing polypeptide derivatives
    US3979447A|1976-09-07|γ-Glutamyl-4-nitroanilide compounds
    Rosenthal1973|The preparation and colorimetric analysis of L-canaline
    JPH0742309B2|1995-05-10|Thiazolidine derivative
    MURAKAMI et al.1981|Studies on absorption promoters for rectal delivery preparations. I. Promoting efficacy of enamine derivatives of amino acids for the rectal absorption of β-lactam antibiotics in rabbits
    US5359121A|1994-10-25|Glycine derivative monosodium salt tetrahydrate
    SU1017168A3|1983-05-07|Process for preparing derivatives of 3,4,5-trioxypiperidine or their salts
    US5382675A|1995-01-17|Polycyclic compounds and processes for the preparation thereof
    AZUMA et al.1977|Polyoxin analogs. III. Synthesis and biological activity of aminoacyl derivatives of polyoxins C and L
    US4801579A|1989-01-31|Novel cystine compounds, their preparation and use
    US4191808A|1980-03-04|Method of measuring dipeptidyl-amino-peptidase activity
    US4180655A|1979-12-25|Nitrosourea derivatives
    Kahns et al.1990|Prodrugs as drug delivery systems. 107. Synthesis and chemical and enzymatic hydrolysis kinetics of various mono-and diester prodrugs of N-acetylcysteine
    Wehrli et al.1987|CGP 4832, a new semisynthetic rifamycin derivative highly active against some Gram-negative bacteria
    US4049702A|1977-09-20|γ-Glutamyl-4-nitroanilide compounds
    Augustinsson et al.1959|Biochemical and pharmacological studies on N-methylated carbamoylcholines
    Kny et al.1959|Chemical and Enzymatic Studies of the Labile Metabolite 4 |-Imidazoline-5-acetic Acid1
    US4292404A|1981-09-29|Method for determining the activity of the angiotensin-converting enzyme
    同族专利:
    公开号 | 公开日
    SU1087074A3|1984-04-15|
    DE2758025A1|1979-07-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2702133C2|2013-09-16|2019-10-04|ЭМЕРГЕНТ ВИРОЛОДЖИ ЭлЭлСи|Deoxynoyirimicin derivatives and methods for use thereof|
    DE3049446A1|1980-12-30|1982-07-29|Bayer Ag, 5090 Leverkusen|METHOD FOR PRODUCING 1,5-DIDESOXY-1,5-IMINO-D-GLUCITOL AND ITS N-DERIVATIVES|
    DE3936295A1|1989-11-01|1991-05-02|Bayer Ag|METHOD FOR PRODUCING INTERMEDIATE PRODUCTS AND SYNTHESISING N--2-HYDROXYMETHYL-3,4,5-TRIHYDROXYPIPERIDINE|
    US7407955B2|2002-08-21|2008-08-05|Boehringer Ingelheim Pharma Gmbh & Co., Kg|8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions|
    US7501426B2|2004-02-18|2009-03-10|Boehringer Ingelheim International Gmbh|8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions|
    US7884115B2|2004-09-28|2011-02-08|Allergan, Inc.|Methods and compositions for the treatment of pain and other neurological conditions|
    DE102004054054A1|2004-11-05|2006-05-11|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Process for preparing chiral 8--xanthines|
    US7772191B2|2005-05-10|2010-08-10|Boehringer Ingelheim International Gmbh|Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein|
    DE102005035891A1|2005-07-30|2007-02-08|Boehringer Ingelheim Pharma Gmbh & Co. Kg|8--xanthines, their preparation and their use as pharmaceuticals|
    PE20080697A1|2006-05-03|2008-08-05|Boehringer Ingelheim Int|BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE|
    PE20080251A1|2006-05-04|2008-04-25|Boehringer Ingelheim Int|USES OF DPP IV INHIBITORS|
    EP1852108A1|2006-05-04|2007-11-07|Boehringer Ingelheim Pharma GmbH & Co.KG|DPP IV inhibitor formulations|
    KR101452915B1|2006-05-04|2014-10-21|베링거 인겔하임 인터내셔날 게엠베하|Polymorphs|
    PE20090938A1|2007-08-16|2009-08-08|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL|
    PE20091730A1|2008-04-03|2009-12-10|Boehringer Ingelheim Int|FORMULATIONS INVOLVING A DPP4 INHIBITOR|
    BRPI0916997A2|2008-08-06|2020-12-15|Boehringer Ingelheim International Gmbh|DPP-4 INHIBITOR AND ITS USE|
    UY32030A|2008-08-06|2010-03-26|Boehringer Ingelheim Int|"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"|
    JP2012502081A|2008-09-10|2012-01-26|ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング|Combination therapy for the treatment of diabetes and related symptoms|
    AR074506A1|2008-12-09|2011-01-19|Gilead Sciences Inc|TOLL TYPE RECEIVERS MODULATORS|
    KR20110103968A|2008-12-23|2011-09-21|베링거 인겔하임 인터내셔날 게엠베하|Salt forms of organic compound|
    AR074990A1|2009-01-07|2011-03-02|Boehringer Ingelheim Int|TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY|
    HUE050287T2|2009-02-13|2020-11-30|Boehringer Ingelheim Int|Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof|
    HUE029381T2|2009-09-30|2017-02-28|Boehringer Ingelheim Int|Method for the preparation of a crystalline form of 1-chloro-4--2--tetrahydrofuran-3-yloxy)benzyl)benzene|
    BR112012007085B8|2009-09-30|2021-05-25|Boehringer Ingelheim Int|processes for the preparation of glycopyranosyl substituted benzyl-benzene derivatives|
    UY32919A|2009-10-02|2011-04-29|Boehringer Ingelheim Int|Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses|
    EP3646859A1|2009-11-27|2020-05-06|Boehringer Ingelheim International GmbH|Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin|
    EP2566469A1|2010-05-05|2013-03-13|Boehringer Ingelheim International GmbH|Combination therapy|
    KR20200028498A|2010-06-24|2020-03-16|베링거 인겔하임 인터내셔날 게엠베하|Diabetes therapy|
    AR083878A1|2010-11-15|2013-03-27|Boehringer Ingelheim Int|VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD|
    UY33937A|2011-03-07|2012-09-28|Boehringer Ingelheim Int|PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS|
    ES2713566T3|2011-07-15|2019-05-22|Boehringer Ingelheim Int|Derivative of substituted dinamic quinazoline, its preparation and its use in pharmaceutical compositions for the treatment of type I and II diabetes|
    US9555001B2|2012-03-07|2017-01-31|Boehringer Ingelheim International Gmbh|Pharmaceutical composition and uses thereof|
    US9192617B2|2012-03-20|2015-11-24|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|
    JP6224084B2|2012-05-14|2017-11-01|ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング|Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome|
    WO2013174767A1|2012-05-24|2013-11-28|Boehringer Ingelheim International Gmbh|A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference|
    US20140303097A1|2013-04-05|2014-10-09|Boehringer Ingelheim International Gmbh|Pharmaceutical composition, methods for treating and uses thereof|
    TR201901110T4|2013-04-05|2019-02-21|Boehringer Ingelheim Int|Therapeutic uses of empagliflozin.|
    EP3110449A1|2014-02-28|2017-01-04|Boehringer Ingelheim International GmbH|Medical use of a dpp-4 inhibitor|
    JP6522732B2|2014-07-11|2019-05-29|ギリアード サイエンシーズ， インコーポレイテッド|Modulators of Toll-like receptors for treating HIV|
    SI3194401T1|2014-09-16|2020-12-31|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|
    BR112018072401A2|2016-06-10|2019-02-19|Boehringer Ingelheim International Gmbh|combinations of linagliptin and metformin|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19772758025|DE2758025A1|1977-12-24|1977-12-24|Tri:hydroxy-piperidine derivs. - useful as glucosidase inhibitors for treating diabetes etc. and as animal feed additives|
    [返回顶部]